Humacyte Inc (HUMA)vsRevolution Medicines Inc (RVMD)
HUMA
Humacyte Inc
$0.57
+0.09%
HEALTHCARE · Cap: $165.73M
RVMD
Revolution Medicines Inc
$203.77
+0.21%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Humacyte Inc generates 186% more annual revenue ($2.12M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
HUMA
Avoid24
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+59.9%
Fair Value
$2.52
Current Price
$0.57
$1.95 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -839.6% — below average capital efficiency
Trading at 16.8x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : HUMA
The strongest argument for HUMA centers on Revenue Growth. Revenue growth of 34.9% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : HUMA
The primary concerns for HUMA are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 2.12 is elevated, increasing financial risk.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
HUMA profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
HUMA carries more volatility with a beta of 2.47 — expect wider price swings.
HUMA is growing revenue faster at 34.9% — sustainability is the question.
HUMA generates stronger free cash flow (-22M), providing more financial flexibility.
Bottom Line
HUMA scores higher overall (24/100 vs 24/100) and 34.9% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Humacyte Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs). These innovative, off-the-shelf products are designed to meet pressing needs in vascular reconstruction and chronic disease management, improving patient outcomes and potentially reducing healthcare expenses. Leveraging its advanced technology platform, Humacyte is strategically positioned to drive innovation in transplantation and tissue engineering, thereby cementing its status as a transformative leader within the rapidly evolving landscape of medical therapies.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?